Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Business Exposures
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Top Common Lead Generation Challenges Every B2B Marketer Faces ↗
Via Talk Markets
Exposures Lead
News headline image
Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares? ↗
Via The Motley Fool
Topics Regulatory Compliance
Tickers SEPN
Exposures Lead Legal Regulatory
News headline image
What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors? ↗
Via The Motley Fool
Topics Regulatory Compliance
Tickers MAZE
Exposures Lead Legal Regulatory
News headline image
Why More Buyers Are Requesting Factory Acceptance Tests (FAT) Before Shipment | Derui Electric
Via AB Newswire
Topics Economy Supply Chain
Exposures Lead Supply Chain
News headline image
Used Transformer Demand Reaches New Highs as Lead Times on New Equipment Stretch Beyond Two Years, Reports Surplus Record
Via AB Newswire
Exposures Lead
News headline image
Medical Hedge Fund Sells 281,000 Shares of Enliven Theapeutics. Is it Time to Sell ELVN? ↗
Via The Motley Fool
Topics Regulatory Compliance
Tickers ELVN
Exposures Lead Legal Regulatory
News headline image
Vereigen Media is a U.S.-based B2B demand generation and lead generation company that helps organizations connect with high-intent decision-makers through first-party data, verified content engagement ↗
Via Talk Markets
Exposures Lead
News headline image
Why B2B Teams Struggle with Lead Quality and Data Trust ↗
Via Talk Markets
Exposures Lead
News headline image
Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors? ↗
Via The Motley Fool
Topics Regulatory Compliance
Tickers MAZE
Exposures Lead Legal Regulatory
News headline image
Caleres (CAL) Q1 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
Tickers CAL
Exposures Financial Lead
News headline image
Enliven Therapeutics' Chief Medical Officer Sold 5,000 Company Shares. Here's What That Means for Investors. ↗
Via The Motley Fool
Topics Regulatory Compliance
Tickers ELVN
Exposures Lead Legal Regulatory
News headline image
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800% ↗
Via The Motley Fool
Topics Regulatory Compliance
Tickers ARGX ERAS INSM MDGL PTCT PTGX
Exposures Lead Legal Regulatory
News headline image
How workforce AI and agentic AI solutions transform operations improve efficiency and scale modern business performance ↗
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence Lead
News headline image
Leadpages Pricing Shapes Smarter Lead Generation Decisions ↗
Via Talk Markets
Exposures Lead
News headline image
Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing ↗
Via The Motley Fool
Topics Regulatory Compliance
Tickers BSX CVS INSM LLY REGN VERA
Exposures Lead Legal Regulatory
News headline image
Champion Homes SKY Q3 2026 Earnings Transcript ↗
Via The Motley Fool
Tickers SKY
Exposures Lead
News headline image
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter ↗
Via The Motley Fool
Topics Regulatory Compliance
Tickers ALMS GH GPCR IMVT PCVX TARS
Exposures Lead Legal Regulatory
News headline image
After a Q1 Blowout and a Soaring Share Price, Is AMD Stock Still a Buy? ↗
Via The Motley Fool
Topics Artificial Intelligence Earnings
Tickers AMD NVDA
Exposures Artificial Intelligence Financial Lead
News headline image
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? ↗
Via The Motley Fool
Tickers ABVX BEAM IMVT PTGX ROIV
Exposures Lead
News headline image
Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? ↗
Via The Motley Fool
Topics ETFs Regulatory Compliance
Tickers ABVX CRNX IMVT PTGX ROIV
Exposures Lead Legal Regulatory
News headline image
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase ↗
Via The Motley Fool
Topics Regulatory Compliance
Tickers CELC CRVS KOD KYMR RVMD TNGX
Exposures Lead Legal Regulatory
News headline image
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally ↗
Via The Motley Fool
Topics Regulatory Compliance
Tickers CELC KOD KYMR RVMD TNGX
Exposures Lead Legal Regulatory
News headline image
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares ↗
Via The Motley Fool
Tickers ABVX COGT MAZE PRAX SYRE
Exposures Lead
News headline image
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
Tickers ABVX COGT GPCR PRAX SYRE
Exposures Lead Legal Regulatory
News headline image
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More ↗
Via The Motley Fool
Topics Regulatory Compliance
Tickers BBOT ERAS EWTX EYPT PRAX
Exposures Lead Legal Regulatory
News headline image
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy ↗
Via The Motley Fool
Topics Regulatory Compliance
Tickers DRUG ERAS PRAX TERN TNGX WHWK
Exposures Lead Legal Regulatory
News headline image
Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares ↗
Via The Motley Fool
Tickers ARGX COGT INSM NKTR ONC ROIV
Exposures Lead
News headline image
Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700% ↗
Via The Motley Fool
Topics Regulatory Compliance
Tickers ERAS EWTX KYMR ONC SRRK
Exposures Lead Legal Regulatory
News headline image
Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120% ↗
Via The Motley Fool
Topics Regulatory Compliance
Tickers DNTH ELVN JBIO ORKA
Exposures Lead Legal Regulatory
News headline image
Capricor's Insider Just Sold Big — Her Options Tell the rest of the Story ↗
Via The Motley Fool
Topics Regulatory Compliance
Tickers CAPR
Exposures Lead Legal Regulatory
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.